22:25 , Apr 13, 2018 |  BioCentury  |  Emerging Company Profile

Reversing Neuropathy

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy. Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016...
22:50 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis In vitro and mouse studies identified a tetrahydrocarboline-based HDAC6 inhibitor that could help treat arthritis. Chemical synthesis and in vitro activity assays of tetrahydrocarboline analogs yielded a compound that inhibited HDAC6 with a...
20:06 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest inhibiting HDAC6 could help treat ALS. In ALS patient-derived motor neurons, inhibition of HDAC6 with two tool compounds or antisense oligonucleotide (ASO)-mediated knockdown decreased axon transport...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
19:19 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies suggest inhibiting HDAC6 could help treat ARID1A -mutant clear cell ovarian cancer. In four ARID1A-mutant clear cell ovarian cancer cell lines, the HDAC6 inhibitor rocilinostat or shRNA...
23:47 , Jul 5, 2017 |  BC Extra  |  Company News

Management tracks

Regenacy Pharmaceuticals LLC (Boston, Mass.) named Simon Jones president and CEO. He was VP of biology at EPIX Pharmaceuticals Inc. (Pink:EPIX). Jones succeeds Walter Ogier, who will remain a director. Last December, Acetylon Pharmaceuticals Inc....
22:05 , Dec 9, 2016 |  BC Week In Review  |  Company News

Acetylon, Celgene deal

Acetylon said Celgene will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston, Mass.). Celgene will gain rights to...
00:07 , Dec 3, 2016 |  BC Extra  |  Company News

Celgene acquiring Acetylon after spinout of newco

Acetylon Pharmaceuticals Inc. (Boston, Mass.) said Celgene Corp. (NASDAQ:CELG) will acquire it for undisclosed terms. Prior to the deal's completion, Acetylon will spin out some histone deacetylase (HDAC) assets into newco Regenacy Pharmaceuticals LLC (Boston,...